Gain Therapeutics, Inc. GANX 深 滬
交易中 09-20 11:25:23 美东时间
1.49
-0.005
-0.33%
華盛通- 最 高1.55
- 今 開1.52
- 成交量 8.12万股
- 最 低 1.49
- 昨 收 1.495
- 總市值 2413.71万
- 52周最高 5.33
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 0.89
- 委 比 -79.61%
- 總股本 1619.94万
- 歷史最高 17.93
- 量 比 1.77
- 振 幅 4.01%
- 歷史最低 0.89
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain slips after early-stage data for Parkinson’s therapy
Gain Therapeutics (NASDAQ:GANX) fell ~12% premarket Thursday after the biotech posted initial data from a Phase 1 trial for its lead asset GT-02287 targeted at Parkinson’s disease. According to Gain (...
08-29 20:33
快讯 | Gain Therapeutics宣布Gt-02287的临床试验阶段1的积极上市结果，这是一种针对帕金森病的新型Gcase靶向小分子治疗药物。
Gain Therapeutics Announces Positive Topline Results From the Phase 1 Clinical ...
08-29 19:30
快讯 | Gain Therapeutics Inc - Gt-02287 第10亿阶段试验将于2024年第4季度开始
Gain Therapeutics Inc - GT-02287 Phase 1B Trial Starts Q4 2024
08-29 19:30
快讯 | Gain Therapeutics Inc：Oppenheimer覆盖，评级为Outperform，目标价$8，相比之下目标价为$9。
Gain Therapeutics Inc : Oppenheimer Assumes Coverage With Outperform Rating; Ta...
08-14 18:39
Gain Therapeutics GAAP EPS of -$0.42
Gain Therapeutics press release (NASDAQ:GANX): Q2 GAAP EPS of -$0.42. Cash, cash equivalent and marketable securities were $16.9 million as of June 30, 2024, compared to $16.8 million as of December 3...
08-08 20:20
Gain Therapeutics Q2 2024 GAAP EPS $(0.42) Misses $(0.20) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 32.26 percent increase over losses of $(0.62) per share from
08-08 19:49
快讯 | Gain Therapeutics报告2024年第二季度财务业绩并提供企业更新
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provide...
08-08 19:30
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
07-11 18:24
快讯 | Gain Therapeutics公司：Maxim Group将目标价从10美元下调至5美元。
Gain Therapeutics Inc : Maxim Group Cuts Target Price to $5 From $10
07-11 13:00
